153 related articles for article (PubMed ID: 8063618)
1. Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Kawamura I; Lacey E; Tanaka Y; Nishigaki F; Manda T; Shimomura K
Jpn J Cancer Res; 1994 Jun; 85(6):639-44. PubMed ID: 8063618
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
3. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
5. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
6. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells.
Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K
Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842
[TBL] [Abstract][Full Text] [Related]
7. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
Parisot JP; Hu XF; Sutherland RL; Wakeling A; Zalcberg JR; DeLuise M
Int J Cancer; 1995 Aug; 62(4):480-4. PubMed ID: 7635575
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
Attardi B; Happe HK
Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
[TBL] [Abstract][Full Text] [Related]
10. Displacement by tamoxifen of the estradiol-estrogen receptor binding: a functional assay for breast cancer studies.
Levin E; Tomchinsky S; López S
J Steroid Biochem Mol Biol; 1990 Dec; 37(5):681-6. PubMed ID: 2278851
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of electrophoretic mobilities of [3H]-estradiol and monohydroxytamoxifen binding components in the cytosols of human breast carcinomas and sera of healthy adult females.
Raam S; D'Agincourt PG; Jordan VC
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1457-65. PubMed ID: 6685632
[TBL] [Abstract][Full Text] [Related]
12. Characterization of estrogen and antiestrogen binding to the cytosol and microsomes of breast tumors.
Lopes MC; Tavares MC; Vale MG; Carvalho AP
J Steroid Biochem Mol Biol; 1991 Sep; 39(3):343-52. PubMed ID: 1911424
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens C1628 and U23,469 in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system.
Rorke EA; Katzenellenbogen BS
Cancer Res; 1981 Apr; 41(4):1257-62. PubMed ID: 6783294
[No Abstract] [Full Text] [Related]
15. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor.
Tate AC; Greene GL; DeSombre ER; Jensen EV; Jordan VC
Cancer Res; 1984 Mar; 44(3):1012-8. PubMed ID: 6692388
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogen-binding sites in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors: relation to growth.
Hwang PL; How BE
Oncology; 1990; 47(6):495-500. PubMed ID: 2123025
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
Lyman SD; Jordan VC
Biochem Pharmacol; 1985 Aug; 34(15):2795-806. PubMed ID: 4015716
[TBL] [Abstract][Full Text] [Related]
18. The two native estrogen receptor forms of 8S and 4S present in cytosol from human uterine tissues display opposite reactivities with the antiestrogen tamoxifen aziridine and the estrogen responsive element.
Navarro D; León L; Chirino R; Fernández L; Pestano J; Díaz-Chico BN
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):49-58. PubMed ID: 9569010
[TBL] [Abstract][Full Text] [Related]
19. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
